Short answer
Aclaris Therapeutics, Inc. (ACRS) filed an 8-K current report with the SEC on March 11, 2026 reporting Item 7.01 (Regulation FD Disclosure). Reg FD disclosure filed March 11, 2026, signed by CFO Kevin Balthaser: no substantive operational or financial data included in the text.
Aclaris Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure filed March 11, 2026, signed by CFO Kevin Balthaser: no substantive operational or financial data included in the text
- Full disclosure content contained in referenced exhibit: investors should review attached exhibit for material information
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aclaris Therapeutics, Inc. 8-K filings
Get the next ACRS 8-K as it lands
Follow ACRS for push alerts, or ask the research agent what this filing means.